Citations

Clear

4847 citation(s) found for "Yu, Eric".

Deep residual inception encoder‐decoder network for amyloid PET harmonization
Shah, Jay , Gao, Fei , Ghisays, Valentina , Luo, Ji , Chen, Yinghua , Lee, Wendy , Zhou, Yuxiang, Reiman, Eric M. , Li, Baoxin , Zhou, Yuxiang , Benzinger, Tammie L.S. , Chen, Kewei , Su, Yi , Wu, Teresa

Mayo Clinic

Alzheimer's & Dementia | February 10, 2022 | Volume: 18 | Issue: 12 | Pages: 2448-2457

10.1002/alz.12564 | PMID 35142053 Get It

AbstractIntroductionMultiple positron emission tomography (PET) tracers are available for amyloid imaging, posing a significant challenge to consensus interpretation and quantitative analysis. We accordingly developed and validated a deep learning model as a harmonization strategy.MethodA Residual Inception Encoder‐Decoder Neural Network was developed to harmonize images between amyloid PET image pairs made with Pittsburgh Compound‐B and florbetapir tracers. The model was trained using a dataset with 92 subjects with 10‐fold cross validation and its generalizability was further examined using an independent external dataset of 46 subjects.ResultsSignificantly stronger between‐tracer correlations (P < .001) were observed after harmonization for both global amyloid burden indices and voxel‐wise measurements in the training cohort and the external testing cohort.DiscussionWe proposed and validated a novel encoder‐decoder based deep model to harmonize amyloid PET imaging data from different tracers. Further investigation is ongoing to improve the model and apply to additional tracers.
Outcomes in post-acute sequelae of COVID-19 (PASC) at 6 months post-infection Part 1: Cognitive functioning
Whiteside, Douglas M. , Basso, Michael R. , Naini, Savana M. , Porter, James N., Holker, Erin , Waldron, Eric J. , Melnik, Tanya E., Niskanen, Natalie, Whiteside, Douglas , Taylor, Sarah E.

Mayo Clinic

The Clinical Neuropsychologist | February 8, 2022 | Volume: 36 | Issue: 4 | Pages: 806-828

10.1080/13854046.2022.2030412 | PMID 35130818 Get It

CT Fractional Flow Reserve: A Practical Guide to Application, Interpretation, and Problem Solving
Rajiah, Prabhakar , Cummings, Kristopher W. , Williamson, Eric E. , Young, Phillip M. , Rajiah, Prabhakar

Mayo Clinic

RadioGraphics | February 4, 2022 | Volume: 42 | Issue: 2 | Pages: 340-358

10.1148/rg.210097 | PMID 35119968 Get It

Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort
Palmowski, Andriko , Wiebe, Edgar , Muche, Burkhard , Hermann, Sandra , Dejaco, Christian , Matteson, Eric L. , Buttgereit, Frank , Dejaco, Christian , Buttgereit, Frank

Mayo Clinic

Cells | February 4, 2022 | Volume: 11 | Issue: 3 | Pages: 536

10.3390/cells11030536 | PMID 35159345 Get It

Background: Glucocorticoids (GCs) can cause osteoporosis (OP). Prior observational research on bone density and the effects of GCs in polymyalgia rheumatica (PMR) and vasculitides is scarce and inconclusive. Methods: Rh-GIOP is a prospective cohort study of bone health in patients with inflammatory rheumatic diseases. In this cross-sectional baseline analysis, we focused on patients with PMR and different forms of vasculitides. Multivariable linear regression was used to model the effect of current and cumulative GC intake on the minimum T-score at any site (mTs; at either lumbar spine or hip), with comprehensive adjustment for confounders. In separate models, GCs were modelled both as continuous and categorical predictors. Sensitivity analyses, stratifying by measurement site and disease, were conducted. Results: A total of 198 patients, with a mean age of 67.7 ± 11.4 years and a mean disease duration of 5.3 ± 6.3 years, were included. Most patients suffered from PMR (36%), giant cell arteritis (26%) or granulomatosis with polyangiitis (17%). Women comprised 66.7% of the patients, and 87.4% were currently taking GCs. The mean CRP was 13.2 ± 26.1 mg/L. OP diagnosed by dual energy X-ray absorptiometry (DXA) (T-score ≤ −2.5) was present in 19.7% of the patients. While 88% were taking vitamin D supplements, calcium supplementation (4%) and treatment with anti-resorptive agents (17%) were relatively infrequent. Only 7% had a vitamin D deficit. Neither current (β(continuous model) = −0.01, 97.5% CI –0.02 to 0.01; p(all models) ≥ 0.49) nor cumulative (β(continuous model) = 0.01, 97.5% CI −0.04 to 0.07; p(all models) ≥ 0.35) GC doses were associated with mTs in any model. CRP was not associated with mTs in any model (p(all models) ≥ 0.56), and no interaction between CRP and GC intake was observed (p for interaction(all models) ≥ 0.32). Across all analyses, lower body mass index (p(all models) ≤ 0.01), history of vertebral fractures (p(all models) ≤ 0.02) and proton-pump inhibitor intake (p(all models) ≤ 0.04) were associated with bone loss. Sensitivity analyses with femoral neck and lumbar spine T-scores as dependent variables led to similar results as the analysis that excluded patients with PMR. Conclusions: In this cohort of PMR and vasculitides, we found a similar prevalence of OP by DXA to the overall elderly German population. Vitamin D supplementation was very common, and vitamin D insufficiency was less frequent than expected in Germans. There was no association between current or cumulative GC intake, CRP and impaired bone density. Proton-pump inhibitors seem to be a major, but somewhat neglected, risk factor for OP and should be given more attention. Our findings require confirmation from longitudinal analyses of the Rh-GIOP and other cohorts.
Multi‐institutional review of non‐hypospadiac penile urethral stricture management and outcomes
Abramowitz, David , Sam, Andre‐Philippe , Pachorek, Mark, Martins, Francisco E. , Angulo, J.C. , Simhan, Jay , Li, Eric , Policastro, Connor, Ramírez-Pérez, E. A. , Burks, Frank , Shetty, Zubin, Venkatesan, K. , Hunter, Craig, Gallegos, Maxx , Foreman, Jordan , Pariser, Joseph J. , MacDonald, Susan M. , Warner, Jonathan N. , Martins, Francisco , Warner, Jonathan, Ruel, Nora H. , Nikolavsky, Dmitriy , Kasabwala, Khushabu , Lopez, Damian

Mayo Clinic

International Journal of Urology | February 3, 2022 | Volume: 29 | Issue: 5 | Pages: 376-382

10.1111/iju.14786 | PMID 35118726 Get It

Objectives Penile urethral stricture disease not associated with hypospadias is rare, and there is a wide range of commonly used surgical repair techniques for this disease. We sought to compile a multi‐institutional database of patients who had surgical correction of strictures in the penile urethra not limited to the meatus, and who had no history of hypospadias, for analysis using the Trauma and Urologic Reconstructive Network of Surgeons length, urethral segment and etiology classification system. Methods A retrospective database from 13 institutions was compiled of patients who had undergone surgical correction of Trauma and Urologic Reconstructive Network of Surgeons length, urethral segment and etiology urethral stricture segments S2b/S2c and excluding E5, with a minimum follow‐up time of 4 months. Failure was defined as cystoscopically confirmed recurrence of a stricture measuring less than 16‐Fr. Results We analyzed 222 patients with a median age of 57 years and a follow‐up of 49 months. The overall surgical success rate was 80.2%. On multivariate analysis, the two variables identified that were predictive of surgical success were stricture length ≤2 cm as well as use of a buccal mucosa graft as compared to use of a fasciocutaneous flap, which had success rates of 83% and 52%, respectively ( P = 0.0004). No statistically significant differences were found based on incisional approach or surgical technique, nor were outcomes different based on etiology or preoperative patient demographics. Conclusions Surgical repair of penile urethral strictures of non‐hypospadiac origin have a favorable overall success rate, at 80.2%. Regardless of incisional approach or surgical technique, all operations appear to have similar outcomes other than repairs using fasciocutaneous flap, which were statistically less successful than those using buccal mucosa graft.
The Suprasellar Meningioma Patient-Reported Outcome Survey: a disease-specific patient-reported outcome measure for resection of suprasellar meningioma
Khalafallah, Adham M. , Rakovec, Maureen , Burapachaisri, Katemanee , Fung, Shirley , Kozachik, Sharon , Valappil, Benita, Abou‐Al‐Shaar, Hussam , Zenonos, Georgios A. , Gardner, Paul A. , Başkaya, Mustafa K. , Dornbos, David , Roxbury, Christopher R. , Overdevest, Jonathan B. , Lee, Victoria S. , Levy, Joshua M. , Thamboo, Andrew , Schlosser, Rodney J. , London, Nyall R. , Wu, Albert W., Mukherjee, Debraj , Levy, Joshua M , Schlosser, Rodney J , Mukherjee, Debraj , Wang, Eric W , Snyderman, Carl H , Choby, Garret , Kuan, Edward C , Gudis, David A. , Huang, Judy , Bettegowda, Chetan , Rowan, Nicholas R.

Mayo Clinic

Journal of Neurosurgery | February 2, 2022 | Volume: 136 | Issue: 6 | Pages: 1551-1559

10.3171/2021.6.jns21517 | PMID 34874673 Get It

OBJECTIVE Suprasellar meningioma resection via either the transcranial approach (TCA) or the endoscopic endonasal approach (EEA) is an area of controversy and active evaluation. Skull base surgeons increasingly consider patient-reported outcomes (PROs) when choosing an approach. No PRO measure currently exists to assess quality of life for suprasellar meningiomas. METHODS Adult patients undergoing suprasellar meningioma resection between 2013 and 2019 via EEA (n = 14) or TCA (n = 14) underwent semistructured interviews. Transcripts were coded using a grounded theory approach to identify themes as the basis for a PRO measure that includes all uniquely reported symptoms. To assess content validity, 32 patients and 15 surgeons used a Likert scale to rate the relevance of items on the resulting questionnaire and the general Patient-Reported Outcomes Measurement Information System–29 (PROMIS29). The mean scores were calculated for all items and compared for TCA versus EEA patient cohorts by using unpaired t-tests. Items on either questionnaire with mean scores ≥ 2.0 from patients were considered meaningful and were aggregated to form the novel Suprasellar Meningioma Patient-Reported Outcome Survey (SMPRO) instrument. RESULTS Qualitative analyses resulted in 55 candidate items. Relative to patients who underwent the EEA, those who underwent the TCA reported significantly worse future outlook before surgery (p = 0.01), tiredness from medications 2 weeks after surgery (p = 0.001), and word-finding and memory difficulties 3 months after surgery (p = 0.05 and < 0.001, respectively). The items that patients who received a TCA were most concerned about included medication-induced lethargy after surgery (2.9 ± 1.3), blurry vision before surgery (2.7 ± 1.5), and difficulty reading due to blurry vision before surgery (2.7 ± 2.7). Items that patients who received an EEA were most concerned about included blurry vision before surgery (3.5 ± 1.3), difficulty reading due to blurry vision before surgery (2.4 ± 1.3), and problems with smell postsurgery (2.9 ± 1.3). Although surgeons overall overestimated how concerned patients were about questionnaire items (p < 0.0005), the greatest discrepancies between patient and surgeon relevance scores were for blurry vision pre- and postoperatively (p < 0.001 and < 0.001, respectively) and problems with taste postoperatively (p < 0.001). Seventeen meningioma-specific items were considered meaningful, supplementing 8 significant PROMIS29 items to create the novel 25-item SMPRO. CONCLUSIONS The authors developed a disease- and approach-specific measure for suprasellar meningiomas to compare quality of life by operative approach. If demonstrated to be reliable and valid in future studies, this instrument may assist patients and providers in choosing a personalized surgical approach.
Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer
Peddi, Parvin F., Fasching, Peter A. , Liu, Duan , Quinaux, Emmanuel, Robert, Nicholas J., Valero, Vicente, Falkson, Carla I. , Brufsky, Adam , Cunningham, Julie M. , Weinshilboum, Richard M., Pienkowski, Tadeusz, Eiermann, Wolfgang, Bee, Valerie, Wang, Xiaoyan, Wang, Liewei, Yang, Eric H. , Slamon, Dennis J., Hurvitz, Sara A., Pieńkowski, Tadeusz , Crown, John , Falkson, Carla , Brufsky, Adam M , Cunningham, Julie M , Martin, Miguel , Yang, Eric , Liu, Duan , Peddi, Parvin F., Fasching, Peter A , Quinaux, Emmanuel, Robert, Nicholas J., Valero, Vicente, Weinshilboum, Richard M., Eiermann, Wolfgang, Bee, Valerie, Wang, Xiaoyan, Wang, Liewei, Slamon, Dennis J., Hurvitz, Sara A.

Mayo Clinic

Clinical Cancer Research | February 2, 2022 | Volume: 28 | Issue: 9 | Pages: 1854-1862

10.1158/1078-0432.ccr-21-1762 | PMID 35110416 Get It

Abstract Purpose: Cardiac toxicity is a serious potential complication of HER2-directed therapies and anthracyclines. HER2 codon 655 and SLC28A3 gene polymorphisms have been reported to be associated with cardiac toxicity from anti-HER2 and anthracycline therapy, respectively. Association of the polymorphism at HER2 codon 655 with prognosis has also been reported. Experimental Design: Whole blood samples from patients treated on a randomized adjuvant breast cancer trial (BCIRG-006) that compared chemotherapy with or without trastuzumab plus either anthracycline or nonanthracycline chemotherapy were tested for genetic polymorphisms in HER2 codon 655 and SLC28A3. Genotypes were correlated with cardiac function and disease-free survival (DFS) outcomes. Results: Of 3,222 patients enrolled in BCIRG-006, 662 patient samples were successfully genotyped for the rs1136201 allele in HER2 (codon 655): 424 (64%) were AA, 30 (4.5%) were GG, and 208 (31%) were AG genotype. In addition, 665 patient samples were successfully genotyped for the rs7853758 allele in the SLC28A3 gene: 19 (3%) were AA, 475 (71%) were GG, and 171 (26%) were AG genotype. Follow-up time was 10 years. No correlation between DFS, cardiac event rate, or mean left ventricular ejection fraction (LVEF) and rs1136201 genotype was seen in the trastuzumab-treated or non–trastuzumab-treated patients. Moreover, mean LVEF and cardiac event rates were similar in all rs7853758 genotype groups treated with anthracycline-based therapy. Conclusions: In the largest study to date to evaluate whether two polymorphisms are associated with DFS and/or cardiac toxicity in HER2-positive breast cancer treated with trastuzumab and/or anthracyclines, we observed no correlation.
Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse
Roselli, Carolina , Yu, Mengyao , Nauffal, Victor , Georges, Adrien , Love, Katie , Weng, Lu‐Chen , Delling, Francesca N. , Maurya, Svetlana , Schrölkamp, Maren , Tfelt‐Hansen, Jacob , Jeunemaı̂tre, Xavier , Debette, Stéphanie , Guan, Wyliena , Body, Simon C. , Shah, Svati H. , Samad, Zainab , Kyryachenko, Sergiy , Haynes, Carol , Rienstra, Michiel , Hamer, Inez J. Wijdh‐den , Siland, Joylene E. , Levine, Robert A. , Benjamin, Emelia J. , Horne, Benjamin D. , Muhlestein, Joseph B. , Benfari, Giovanni , Natale, Andrea , Trivedi, Chintan , Shoemaker, Moore B., Yoneda, Zachary T. , Baker, Michael , Slaugenhaupt, Susan, Dina, Christian , Lubitz, Steven A. , Bouatia‐Naji, Nabila , Milan, David J. , Yang, Qiong , Love, Katie , Weng, Lu-Chen , Delling, Francesca N , Maurya, Svetlana R , Schrölkamp, Maren , Tfelt-Hansen, Jacob , Debette, Stephanie , Amouyel, Philippe , Guan, Wyliena , Muehlschlegel, Jochen D , Body, Simon C , Shah, Svati , Kyryachenko, Sergiy , Haynes, Carol , Rienstra, Michiel , Le Tourneau, Thierry , Wijdh-Den Hamer, Inez J , Siland, Joylene E , Jacques Schott, Jean , Levine, Robert A , Benjamin, Emelia J , Vasan, Ramachandran S , Horne, Benjamin D , Muhlestein, Joseph B , Benfari, Giovanni , Enriquez-Sarano, Maurice , Yoneda, Zachary T , Baker, Michael T , Farber-Eger, Eric H , Norris, Russell A , Dina, Christian , Lubitz, Steven A , Bouatia-Naji, Nabila , Ellinor, Patrick T , Natale, Andrea , Hagège, Albert Alain , Amouyel, Philippe , Tourneau, Thierry Le , Probst, Vincent , Roussel, Ronan , Knowlton, Kirk U. , Schott, Jean‐Jacques , Vasan, Ramachandran S. , Enriquez‐Sarano, Maurice , Mohanty, Sanghamitra , Wells, Quinn S. , Farber‐Eger, Eric , Michelena, Héctor I. , Lundby, Alicia , Ellinor, Patrick T.

Mayo Clinic

European Heart Journal | February 1, 2022 | Volume: 43 | Issue: 17 | Pages: 1668-1680

10.1093/eurheartj/ehac049 | PMID 35245370 Get It

Abstract Aims Mitral valve prolapse (MVP) is a common valvular heart disease with a prevalence of &gt;2% in the general adult population. Despite this high incidence, there is a limited understanding of the molecular mechanism of this disease, and no medical therapy is available for this disease. We aimed to elucidate the genetic basis of MVP in order to better understand this complex disorder. Methods and results We performed a meta-analysis of six genome-wide association studies that included 4884 cases and 434 649 controls. We identified 14 loci associated with MVP in our primary analysis and 2 additional loci associated with a subset of the samples that additionally underwent mitral valve surgery. Integration of epigenetic, transcriptional, and proteomic data identified candidate MVP genes including LMCD1, SPTBN1, LTBP2, TGFB2, NMB, and ALPK3. We created a polygenic risk score (PRS) for MVP and showed an improved MVP risk prediction beyond age, sex, and clinical risk factors. Conclusion We identified 14 genetic loci that are associated with MVP. Multiple analyses identified candidate genes including two transforming growth factor-β signalling molecules and spectrin β. We present the first PRS for MVP that could eventually aid risk stratification of patients for MVP screening in a clinical setting. These findings advance our understanding of this common valvular heart disease and may reveal novel therapeutic targets for intervention.
Does a truly hippocampal sparing subtype of Alzheimer’s disease really exist?
Ferreira, Daniel , Mohanty, Rosaleena , Murray, Melissa E. , Nordberg, Agneta , Kantarci, Kejal , Westman, Eric

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.056368 Get It

AbstractBackgroundThe field of biological subtypes of Alzheimer’s disease (AD) has recently gained attention as a strong driver of precision medicine and future clinical trials. Neuropathology and neuroimaging studies have consistently identified four subtypes: hippocampal sparing AD, typical AD, limbic predominant AD, and minimal atrophy or minimal tau NFT AD. An important and still unresolved question is whether a truly hippocampal sparing subtype of AD can really exist, since it would challenge the widely accepted model of NFT spread. To address this question, we conducted a systematic review of the literature and performed original analyses on tau PET data.MethodOur systematic review included a search on EMBASE, PubMed, and Web of Science databases up to October 2020. Original analyses included implementation of several methods for AD subtyping on tau PET, and utilization of five complementary cut points to identify hippocampal sparing AD cases both in published studies and in data from the Alzheimer's Disease Neuroimaging Initiative (ADNI).ResultIn the three reviewed neuropathologic studies, we did not find any individual case with tau NFT in the association cortex while completely sparing the hippocampus (i.e., truly hippocampal sparing cases). In the in vivo tau PET studies, more lenient cut points consistently identified AD patients with tau NFT in the association cortex while completely sparing the hippocampus.ConclusionOur current data suggests that the hippocampal sparing subtype of AD does exist ante‐mortem, at earlier stages of the disease, but more research is needed to understand its pathogenesis and progression during life. Based on the findings from both in vivo tau PET and neuropathologic studies, we suggest that there are two possible independent pathways of tau spread: (1) a canonical pathway with early involvement of entorhinal cortex with subsequent involvement of limbic regions before eventually affecting multimodal association cortices, and (2) a less common pathway that affects multimodal association cortices with limbic involvement observed at end stages of the disease. As emphasized in the Murray 2011 study, hippocampal sparing relative to greater cortical involvement defines the phenotype.